The copolymer of epsilon-caprolactone-lactide and tricalcium phosphate does not enhance bone growth in mandibular defect of sheep.
In the field of craniomaxillofacial and orthopaedic surgery there is a constant need for bone or bone substitute. At the present, the most effective way to enhance bone healing clinically is to use autogenous bone grafts. The problems associated with the use of these autografts are donor site morbidity, limited supply and need for a second operative site. Currently there are several different synthetic products commercially available in the market; nevertheless, none of them is ideal for filling bone defects. Therefore, search for new synthetic materials for bone replacement is necessary. A mixture of tricalcium phosphate (TCP) and epsilon-caprolactone-lactide copolymer P(epsilon -CL/DL-LA) was prepared and implanted in critical size mandibular bone defects in twelve sheep. Contralateral side was used as a control. Follow-up times for histological and radiological studies were 9, 14, 24 and 52 weeks. We found that the implanted material did not enhance bone formation compared to control site. We also confirmed that defect size was of critical size, since there was no complete healing of the control site either. The results do not encourage us to continue our studies with the mixture of TCP and P(epsilon-CL/DL-LA) as a filling material for bone defects. Therefore the search for the ideal material is still ongoing.
Ekholm
M
M
Department of Oral and Maxillofacial Surgery, Helsinki University Central Hospital, Finland.
Hietanen
J
J
Tulamo
R-M
RM
Muhonen
J
J
Lindqvist
C
C
Kellomäki
M
M
Suuronen
R
R
D000818:Animals; D001665:Binding Sites; D001846:Bone Development; D001861:Bone Regeneration; D018786:Bone Substitutes / Q000737:chemistry*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002130:Calcium Phosphates / Q000737:chemistry* / Q000378:metabolism; D004195:Disease Models, Animal; D007249:Inflammation; D008334:Mandible / Q000378:metabolism*; D008336:Mandibular Diseases / Q000628:therapy*; D010006:Osteoblasts / Q000378:metabolism; D011091:Polyesters / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012756:Sheep; D013997:Time Factors
D018786:Bone Substitutes; D002130:Calcium Phosphates; D011091:Polyesters; D011108:Polymers; C505727:poly(epsilon-caprolactone-co-lactide); C018392:tricalcium phosphate